Imaging in psychiatric illnesses

International Journal of Clinical Practice

Volumn 58, Issue 9, 2004, Pages 850-858

  Gupta, Abhaya ^a   Elheis, M ^a   Pansari, K ^b  

^a WEST WALES GENERAL HOSPITAL   (United Kingdom)

^b St Davids Hospital   (United Kingdom)

Author keywords

Brain; Imaging; Psychiatry

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; FLUOXETINE;

ALZHEIMER DISEASE; BRAIN FUNCTION; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIAGNOSTIC VALUE; DRUG METABOLISM; FRONTOTEMPORAL DEMENTIA; HUMAN; MENTAL DISEASE; MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 7744239872     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00224.x     Document Type: Review

References (89)

1. Johnstone EC, Crow TJ, Frith CD et al. Cerenral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 1976; ii: 924-6.
2. McCarley RW, Wible CG, Frumin M et al. MRI anatomy of schizophrenia. Biol Psychiatry 1999; 45: 1099-119.
3. Wright IC, Rabe-Hesketh S, Woodruff PW et al. Meta-analysis of regional brain Volumes in Schizophrenia. Am J Psychiatry 2000; 157: 16-25.
4. Copolov D, Crook J. Biological markers and Schizophrenia. Aust N Z J Psychiatry 2000; 34: S108-12.
5. Sumich A, Chitnis XA, Lowe J et al. Temporal lobe structures, symptomatology and first episode psychosis. Schizophr Res 2000; 41: 113-4.
6. Fannon D, Chitnis X, Doku V et al. Features of structural brain abnormality detected in first episode psychosis. Am J Psychiatry 2000; 157: 1829-34.
7. Ettinger U, Chitnis X, Kumari V et al. Magnetic resonance imaging of the thalamus in first episode psychosis. Am J Psychiatry 2001; 158: 116-8.
8. Andreasen N. The role of the thalamus in schizophrenia. Can J Psychiatry 1997; 42: 27-33.
9. Mathalon DH, Sullivan EV, Lim KO et al. Progressive brain Volume changes and the clinical course of schizophrenia in men: a longitudinal MRI study. Arch Gen Psychiatry 2001; 58: 148-57.
10. Fannon D, Tennakoon L, Sumich A et al. Third ventricle enlargement and developmental delay in first episode psychosis. Br J Psychiatry 2000; 177: 354-9.
11. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 1974; 50: 425-62.
12. Andreason NC, Rezai K, Alliger R et al. Hypofrontality in neuroleptic naïve patients and in patients with chronic schizophrenia. Arch Gen Psychiatry 1992; 49: 943-58.
13. Woodruff PW, Wright WC, Bullmore ET et al. Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. Am J Psychiatry 1997; 154: 1676-82.
14. Yurgelun-Todd DA, Waternaux CM, Cohen BM et al. Functional MRI of schizophrenic patients and comparison subjects during word production. Am J Psychiatry 1996; 153 (2): 200-5.
15. Carter CS, Perlstein W, Ganguli R et al. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry 1998; 155 (9): 1285-7.
16. Fletcher PC, McKenna PJ, Frith CD et al. Brain activations in schizophrenia during a graded memory task studied with functional neuroimaging. Arch Gen Psychiatry 1998; 55 (11): 1001-8.
17. Wenz F, Schad LR, Knopp MV et al. Functional MRI at 1.5T: activation pattern in schizophrenic patients receiving neuroleptic medications. Magn Reson Med 1994; 12: 975-82.
18. Bertolino A, Callicott JH, Ellman I et al. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 1998; 43 (9): 641-8.
19. Cecil KM. Lenkinski RE, Gur RE et al. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naïve patients with schizophrenia. Neuropsychopharmacology 1999; 20 (2): 131-40.
20. Callicott JH, Bertolino A, Egan MF et al. A selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry 2000; 157 (10): 1646-51.
21. Honey GD, Bullmore ET, Soni W et al. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 1999; 96: 13432-7.
22. Phillips ML, Williams L, Senior C et al. A differential neural response to threatening and nonthreatening negative facial expressions in paranoid and nonparanoid schizophrenics. Psych Res Neuroimaging 1999; 92 (8): 11-31.
23. Soares JC, Mann J. The anatomy of mood disorders. Review of structural neuroimaging studies. Biol Psychiatry 1997; 41: 86-106.
24. Sheline YI, Wang PW, Gado MH et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-13.
25. Brenner JD, Narayan M, Anderson ER et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000; 157: 115-7.
26. Sheline YI, Shangavi M, Mintun MA et al. Depression duration but not age predicts hippocampal Volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19: 5034-43.
27. Altschuler LL, Bartzokis G, Grieder T et al. Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: an MRI study demonstrating neuroanatomic specificity. Arch Gen Psychiatry 1998; 55: 663-4.
28. Coffey CE, Wilkinson WE, Weiner RD et al. Quantitative cerebral anatomy in depression: a controlled MRI study. Arch Gen Psychiatry 1993; 50: 7-16.
29. Dahabra S, Ashton CH, Bahrainian M et al. Structural and functional abnormalities in elderly patients clinically recovered from early and late onset depression. Biol Psychiatry 1998; 44: 34-46.
30. Lane RD, Reiman EM, Ahern GL et al. Neuroanatomical correlates of happiness, sadness and disgust. Am J Psychiatry 1997; 154: 926-33.
31. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med 1998; 49: 341-61.
32. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry 1997; 9: 471-81.
33. Beauregard M, Leroux JM, Bergman S et al. The functional neuroanatomy of major depression: an fMRI study using an emotional activation paradigm. Neuroreport 1998; 9: 3253-8.
34. Kennedy SH, Evans KR, Krueger S et al. Changes in regional brain glucose metabolism, measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001; 158: 899-905.
35. Kumari V, Mitterschiffthaler MT, Teasdale JD et al. Cognitive generation of affect in depression. A Func MRI Study. Biol Psychiatry 2001; 49 (8 Suppl.): 105S.
36. Sheline YI, Barch DM, Donnolly JM et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001; 50: 651-8.
37. Kimbrell TA, Ketter TA, George MS et al. Regional cerebral glucose utilisation in patients with a range of seventies of unipolar depression. Biol Psychiatry 2002; 51: 237-52.
38. Mayberg HS, Brannan SK, Tekell JL et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000; 48: 830-43.
39. Mayberg HS, Liotti M, Brannan SK et al. Reciprocal limbiccortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156: 675-82.
40. Pizzagali D, Pascaul-Marqui RD. Nitschke JB et al. Anterior cingulate activity is a predictor of degree of treatment in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 2001; 158: 405-15.
41. Woods BT, Brennan S, Yurgelun-Todd D. MRI abnormalities in major psychiatric disorders: an explorative comparative study. J Neuropsychiatry Clin Neurosci 1995; 7: 49.
42. Kemperman I, Silberswig D, Stern E et al. Brain imaging and personality disorders. In: Krishnan KR, Doraiswamy PM, eds. Brain Imaging in Clinical Psychiatry. New York: Marcel Dekker 1997, 477-503.
43. Raine A, Lencz T, Bihrle S et al. Reduced prefrontal grey matter Volume and reduced autonomic activity in antisocial personality disorder. Arch Gen Psychiatry 2000; 57 (2): 119-27.
44. Raine A. Psychopathology of Crime: Criminal Behaviour as a Clinical Disorder. California: Academic Press 1993.
45. Goyer PF, Andreason PJ, Semple WE et al. Positron Emission Tomography and personality disorders. Neuropsychopharmacology 1994; 10 (1): 21-8.
46. Raine A, Phil D, Stoddard J et al. Prefrontal glucose deficits in murderers lacking psychosocial deprivation. Neuropsychiatry Neuropsychol Behav Neurol 1998; 11 (1): 1-7.
47. Intrator J, Hare R, Stritzke P et al. A brain imaging study of semantic and affective processing psychopaths. Biol Psychiatry 1997; 42 (2): 96-103.
48. Kiehl KA. Aneuroimaging investigation of affective cognitive and language functions in psychopathy. Diss Abstract Int B Sci Eng 2000; 61 (5B): 2766.
49. Schneider F, Habel U, Kessler C et al. Functional imaging of conditioned aversive emotional responses in antisocial personality disorder. Neuropsychobiology 2000; 42 (4): 192-201.
50. Cammor BE. The ability of CT scan in diagnosing dementia. Mount Sinai J Med 1997; 64: 372-5.
51. Katzman R. Should a major imaging procedure (CT or MRI) be required in the workup of dementia? An affirmative view. J Fam Prac 1990; 31: 401-4.
52. Farina E, Pomati S, Mariani C. Observations on dementias with possible reversible symptoms. Aging 1999; 11: 323-8.
53. Lopez O, Becker JT, Jungreis CA et al. Computed Tomography but not MRI identified periventricular white matter lesions predict symptomatic cerebrovascular disease in probable Alzhiemer's disease. Arch Neurol 1995; 52: 659-64.
54. Corey-Bloom J, Thal LJ, Galasko D et al. Diagnosis and evaluation of dementia. Neurology 1995; 45: 211-8.
55. Foster GR, Scott DA, Payne S. The use of CT scanning in dementia. A systematic review. Int J Technol Assess Health Care 1999; 15: 406-23.
56. Bobinski M, deLeon MJ, Tarnawski M et al. Neuronal and Volume loss in CAI of hippocampal formation uniquely predicts duration and severity of Alzhiemer's disease. Brain Res 1998; 805: 267-9.
57. Jack CR, Petersen RC, Xu YC et al. Rate of medial temporal lobe atrophy in typical ageing and Alzhiemer's disease. Neurology 1998; 51: 993-9.
58. Frisoni GB, Laakso MP, Beltramello A et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzhiemer's disease. Neurology 1999; 52: 91-100.
59. Barber R, Gholkar A, Scheltens P et al. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies: a comparison with Alzhiemer's disease, vascular dementia and normal ageing. Neurology 1999; 52: 1153-8.
60. Petersen RC, Jack CR, Xu YC et al. Memory and MRI based hippocampal Volumes in aging and Alzhiemer's disease. Neurology 2000; 54: 581-7.
61. Jack CR Jr, Dickson DW, Parisi JE et al. Antemortem MRI findings correlate with hippocampal neuropathology in normal ageing and dementia. Neurology 2002; 58: 750-7.
62. Fox NC, Scahill RI, Crum WR et al. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999; 52 (8): 1687-9.
63. Moffat SD, Szekely CA, Zonderman AB et al. Longitudinal change in hippocampal Volume as a function of apolipoprotein E genotype. Neurology 2000; 55 (1): 134-6.
64. Parnetti L, Lowenthal D, Prescuitti O et al. H-MRS. MRI based hippocampal volume try and Tc HMPAO-SPECT in normal ageing, age associated memory impairment and probable Alzhiemer's disease. JAGS 1996; 44: 133-8.
65. Yamaguchi S, Meguro K, Itoh M et al. Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzhiemer's disease as shown by MRI and PET. J Neurol, Neurosurgery Psychiatry 1997; 62: 596-600.
66. Ashford JW, Shih WJ, Coupal J et al. Single SPECT measures of cerebral cortical perfusion reflect time index estimation of dementia severity in Alzhiemer's disease. J Nucl Med 2000; 41: 57-64.
67. DeToledo-Morrell L, Goncharova I, Dickerson B et al. From healthy ageing to early Alzhiemer's disease: in vivo detection of entorhinal cortex atrophy. Ann N Y Acad Sci 2000; 911: 240-53.
68. Jack CR, Peresen RC, Xu Y et al. Rates of hippocampal atrophy correlate with change in clinical status in ageing and AD. Neurology 2000; 55 (4): 484-9.
69. Xu Y, Jack CR, O'Brien PC et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000; 54: 1760-7.
70. Jack CJ, Peterson R, Xu Y et al. Rate of medial temporal lobe atrophy in typical ageing and Alzhiemer's disease. Neurology 1998; 51: 933-9.
71. Geroldi C, Pihlajamaki M, Laasko MP et al. APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999; 53 (8): 1825-32.
72. Convit A, De Asis J, de Leon MJ et al. Atrophy of the medial occipitotemporal, inferior and middle temporal gyri in nondemented elderly predict decline to Alzhiemer's disease. Neubiol Aging 2000; 21 (1): 19-26.
73. Killiany RJ, Gomez-Isla T, Moss M et al. Use of structural magnetic resonance imaging to predict who will get Alzhiemer's disease. Ann Neurol 2000; 47 (4): 430-9.
74. Fazekas F, Alavi A, Chawluk JB et al. Comparison of CT, MRI and PET in Alzhiemer's dementia and normal ageing. J Nucl Med 1989; 30 (10): 1607-15.
75. de Leon MJ, Convit A, Wolf AT et al. Prediction of cognitive decline in normal elderly subjects with FDG/PET. Proc Natl Acad Sci USA 2001; 286: 2120-7.
76. Johnson KA, Jones K, Holman BL et al. Preclinical prediction of Alzhiemer's disease using SPECT. Neurology 1998; 50: 1563-71.
77. Johnson SC, Saykin AJ, Baxter LC et al. The relationship between fMRI activation and cerebral atrophy: comparison of normal ageing and Alzhiemer's disease. Neuroimage 2000; 11: 179-87.
78. De Stefano N, Mortilla M, Federico A. Proton Magnetic resonance Spectroscopy of the brain in dementia. Ital J Neurol Sci 1999; 20: S258-S264.
79. Jessen F, Block W, Traber F et al. Proton MRI spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000; 55 (5): 684-8.
80. Kuhl DE, Koeppe RA, Minoshima S et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzhiemer's disease. Neurology 1999; 52: 691-9.
81. Potkin SG. Anand R, Fleming K et al. Brain metabolic and clinical effects of rivastigmine in Alzhiemer's disease. Int J Neuropsychopharmacol 2001; 3: 23-30.
82. Schuff N, Du AT, Amend D et al. MRI of entorhinal cortex and hippocampus in Alzhiemer's disease, subcortical ischemic vascular dementia and mixed dementia. In: Iqbal K, Sisodia SS, Winblad B, eds. Alzhiemer's Disease: Advances in Etiology, Pathogenesis and Therapeutics Chichester: John Wiley and sons 2001, 229-36.
83. Barber R, Ballard C, McKeith IG et al. MRI volumetric study of dementia with Lewy bodies. A comparison with AD and vascular dementia. Neurology 2000; 54: 1304-9.
84. Mungas D, Jagust WJ, Reed BR et al. MRI predictors of cognition in subcortical ischemic vascular disease and Alzhiemer's disease. Neurology 2001; 57: 2229-35.
85. Middelkoop HAM, van der Flier WM, Burton EJ et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 2001; 75: 2117-20.
86. Obrien JT, Paling S, Barber R et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD and vascular dementia. Neurology 2001; 56: 1386-8.
87. Galton CJ, Gomez-Anson B, Antoun N et al. Temporal lobe rating scale: application to Alzhiemer's disease and frontoremporal dementia. J Neurol Neurosurg Psychiatry 2001; 70: 165-73.
88. Jaus M, Herholz K, Kracht L et al. Frontotemporal dementia: clinical, neuroimaging and molecular biological findings in 6 patients. Eur Arch Psychiatry Clin Neurosci 2001; 251: 225-31.
89. Ernst T, Chang L, Melchor R et al. Frontotemporal dementia and early Alzhiemer's disease: differentiation with frontal lobe H-1 MRS. Radiology 1997; 203: 829-36.